A pilot radiometabolomics integration study for the characterization of renal oncocytic neoplasia.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
20
01
2023
accepted:
31
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Differentiating benign renal oncocytic tumors and malignant renal cell carcinoma (RCC) on imaging and histopathology is a critical problem that presents an everyday clinical challenge. This manuscript aims to demonstrate a novel methodology integrating metabolomics with radiomics features (RF) to differentiate between benign oncocytic neoplasia and malignant renal tumors. For this purpose, thirty-three renal tumors (14 renal oncocytic tumors and 19 RCC) were prospectively collected and histopathologically characterised. Matrix-assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI) was used to extract metabolomics data, while RF were extracted from CT scans of the same tumors. Statistical integration was used to generate multilevel network communities of -omics features. Metabolites and RF critical for the differentiation between the two groups (delta centrality > 0.1) were used for pathway enrichment analysis and machine learning classifier (XGboost) development. Receiver operating characteristics (ROC) curves and areas under the curve (AUC) were used to assess classifier performance. Radiometabolomics analysis demonstrated differential network node configuration between benign and malignant renal tumors. Fourteen nodes (6 RF and 8 metabolites) were crucial in distinguishing between the two groups. The combined radiometabolomics model achieved an AUC of 86.4%, whereas metabolomics-only and radiomics-only classifiers achieved AUC of 72.7% and 68.2%, respectively. Analysis of significant metabolite nodes identified three distinct tumour clusters (malignant, benign, and mixed) and differentially enriched metabolic pathways. In conclusion, radiometabolomics integration has been presented as an approach to evaluate disease entities. In our case study, the method identified RF and metabolites important in differentiating between benign oncocytic neoplasia and malignant renal tumors, highlighting pathways differentially expressed between the two groups. Key metabolites and RF identified by radiometabolomics can be used to improve the identification and differentiation between renal neoplasms.
Identifiants
pubmed: 37537362
doi: 10.1038/s41598-023-39809-9
pii: 10.1038/s41598-023-39809-9
pmc: PMC10400617
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12594Informations de copyright
© 2023. Springer Nature Limited.
Références
Gore, M. E. & Larkin, J. M. G. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br. J. Cancer 104, 399–406 (2011).
pubmed: 21285971
pmcid: 3049574
doi: 10.1038/sj.bjc.6606084
Trpkov, K. et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod. Pathol. 34, 1167–1184 (2021).
pubmed: 33526874
doi: 10.1038/s41379-021-00737-6
Roussel, E. et al. Novel imaging methods for renal mass characterization: A collaborative review. Eur. Urol. 81, 476–488 (2022).
pubmed: 35216855
pmcid: 9844544
doi: 10.1016/j.eururo.2022.01.040
Abou-Elkassem, A. M. et al. Role of imaging in renal cell carcinoma: A multidisciplinary perspective. Radiographics 41, 1387–1407 (2021).
pubmed: 34270355
doi: 10.1148/rg.2021200202
Williamson, S. R. et al. Report from the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. III. Molecular Pathology of Kidney Cancer. Am. J. Surg. Pathol. 44, e47–e65 (2020).
pubmed: 32251007
pmcid: 7289677
doi: 10.1097/PAS.0000000000001476
Vogel, C. et al. Imaging in suspected renal-cell carcinoma: Systematic review. Clin. Genitour. Cancer 17, e345–e355 (2019).
doi: 10.1016/j.clgc.2018.07.024
Amin, J. et al. Identification and validation of radiographic enhancement for reliable differentiation of CD117(þ) benign renal oncocytoma and chromophobe renal cell carcinoma. Clin. Cancer Res. 24, 3898–3907 (2018).
pubmed: 29752278
pmcid: 7951998
doi: 10.1158/1078-0432.CCR-18-0252
Trpkov, K. & Hes, O. New and emerging renal entities: A perspective post-WHO 2016 classification. Histopathology 74, 31–59 (2019).
pubmed: 30565301
doi: 10.1111/his.13727
Gill, A. J. et al. The 2022 world health organization classification of tumours of the urinary system and male genital organs—part a: Renal, penile, and testicular tumours. Eur. Urol. https://doi.org/10.1016/j.eururo.2022.06.016 (2022).
doi: 10.1016/j.eururo.2022.06.016
pubmed: 36202688
Hes, O. & Trpkov, K. Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities. Mod. Pathol. 35, 1140–1150 (2022).
pubmed: 35273336
doi: 10.1038/s41379-022-01057-z
Ruiz-Cordero, R. et al. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod. Pathol. 32, 1698–1707 (2019).
pubmed: 31231128
doi: 10.1038/s41379-019-0304-y
Kutikov, A. et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology 68, 737–740 (2006).
pubmed: 17070344
doi: 10.1016/j.urology.2006.04.011
Rosenkrantz, A. B. et al. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR Am. J. Roentgenol. 195, W421–W427 (2010).
pubmed: 21098174
doi: 10.2214/AJR.10.4718
Israel, G. M. & Bosniak, M. A. Pitfalls in renal mass evaluation and how to avoid them. Radiographics 28, 1325–1338 (2008).
pubmed: 18794310
doi: 10.1148/rg.285075744
Young, J. R. et al. Clear cell renal cell carcinoma: Discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. Radiology 267, 444–453 (2013).
pubmed: 23382290
doi: 10.1148/radiol.13112617
Liu, X. et al. Urine metabolomics for renal cell carcinoma (RCC) prediction: Tryptophan metabolism as an important pathway in RCC. Front. Oncol. 9, 1–9 (2019).
Papathomas, T. et al. In situ metabolomics expands the spectrum of renal tumours positive on 99mTc-sestamibi single photon emission computed tomography/computed tomography examination. Eur. Urol. Open Access 22, 88–96 (2020).
doi: 10.1016/j.euros.2020.11.001
Satter, K. B. et al. Oncocytoma-related gene signature to differentiate chromophobe renal cancer and oncocytoma using machine learning. Cells 11, 875 (2022).
doi: 10.3390/cells11020287
Mühlbauer, J. et al. Radiomics in renal cell carcinoma—a systematic review and meta-analysis. Cancers (Basel) 13, 1–15 (2021).
doi: 10.3390/cancers13061348
Kocak, B. et al. Radiomics of renal masses: Systematic review of reproducibility and validation strategies. AJR Am. J. Roentgenol. 214, 129–136 (2020).
pubmed: 31613661
doi: 10.2214/AJR.19.21709
Uhlig, J. et al. Discriminating malignant and benign clinical T1 renal masses on computed tomography: A pragmatic radiomics and machine learning approach. Medicine 99, 1–8 (2020).
doi: 10.1097/MD.0000000000019725
Ursprung, S. et al. Radiomics of computed tomography and magnetic resonance imaging in renal cell carcinoma—a systematic review and meta-analysis. Eur. Radiol. 30, 3558–3566 (2020).
pubmed: 32060715
pmcid: 7248043
doi: 10.1007/s00330-020-06666-3
Jaggi, A. et al. Quantitative image features from radiomic biopsy differentiate oncocytoma from chromophobe renal cell carcinoma. J. Med. Imaging 8, 054501 (2021).
doi: 10.1117/1.JMI.8.5.054501
Uhlig, J. et al. Radiomic features and machine learning for the discrimination of renal tumor histological subtypes: A pragmatic study using clinical-routine computed tomography. Cancers (Basel) 12, 3010 (2020).
pubmed: 33081400
doi: 10.3390/cancers12103010
Zabihollahy, F., Schieda, N., Krishna, S. & Ukwatta, E. Automated classification of solid renal masses on contrast-enhanced computed tomography images using convolutional neural network with decision fusion. Eur. Radiol. 30, 5183–5190 (2020).
pubmed: 32350661
doi: 10.1007/s00330-020-06787-9
Yap, F. Y. et al. Quantitative contour analysis as an image-based discriminator between Benign and malignant renal tumors. Urology 114, 121–127 (2018).
pubmed: 29305199
doi: 10.1016/j.urology.2017.12.018
Yu, H. et al. Texture analysis as a radiomic marker for differentiating renal tumors. Abdom. Radiol. (N.Y.) 42, 2470–2478 (2017).
doi: 10.1007/s00261-017-1144-1
Deng, Y. et al. Usefulness of CT texture analysis in differentiating benign and malignant renal tumours. Clin. Radiol. 75, 108–115 (2020).
pubmed: 31668402
doi: 10.1016/j.crad.2019.09.131
Li, Y., Huang, X., Xia, Y. & Long, L. Value of radiomics in differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Abdom. Radiol. (N.Y.) 45, 3193–3201 (2020).
doi: 10.1007/s00261-019-02269-9
Sasaguri, K. et al. Small (<4 cm) renal mass: Differentiation of oncocytoma from renal cell carcinoma on biphasic contrast-enhanced CT. AJR Am. J. Roentgenol. 205, 999–1007 (2015).
pubmed: 26496547
doi: 10.2214/AJR.14.13966
Dehghani-Firouzabadi, F. et al. CT radiomics for differentiating oncocytoma from renal cell carcinomas: Systematic review and meta-analysis. Clin. Imaging 94, 9–17 (2023).
pubmed: 36459898
doi: 10.1016/j.clinimag.2022.11.007
Oikonomou, E. K. et al. A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CTangiography. Eur. Heart J. 40, 3529–3543 (2019).
pubmed: 31504423
pmcid: 6855141
doi: 10.1093/eurheartj/ehz592
Trivizakis, E., Souglakos, I., Karantanas, A. H. & Marias, K. Deep radiotranscriptomics of non-small cell lung carcinoma for assessing molecular and histology subtypes with a data-driven analysis. Diagnostics 11, 89 (2021).
doi: 10.3390/diagnostics11122383
Kayadibi, Y. et al. Radioproteomics in breast cancer: Prediction of Ki-67 expression with MRI-based radiomic models. Acad. Radiol. 29, S116–S125 (2022).
pubmed: 33744071
doi: 10.1016/j.acra.2021.02.001
Luna, A. Radiogenomics applied to select abdominal tumors. Radiographics 40, 1627–1630 (2020).
pubmed: 33001793
doi: 10.1148/rg.2020200194
Zhang, M. et al. MRI radiogenomics of pediatric medulloblastoma: A multicenter study. Radiology 2022, 212137. https://doi.org/10.1148/radiol.212137 (2022).
doi: 10.1148/radiol.212137
Kickingereder, P. et al. Radiogenomics of glioblastoma: Machine learning–based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology 281, 907–918 (2016).
pubmed: 27636026
doi: 10.1148/radiol.2016161382
Curtis, P., Bigelow, K., Cook, B. A. T. S., Flanders, A. E. & Matthew, P. A roadmap for the foundational research on artifical intelligence in medical imaging: From the 2018 NIH/RSNA/ACR/The Academy workshop. Radiology 291, 781–791 (2019).
doi: 10.1148/radiol.2019190613
Yamada, R., Okada, D., Wang, J., Basak, T. & Koyama, S. Interpretation of omics data analyses. J. Hum. Gen. 66, 93–102 (2021).
doi: 10.1038/s10038-020-0763-5
Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: Images are more than pictures, they are data. Radiology 278, 563–577 (2016).
pubmed: 26579733
doi: 10.1148/radiol.2015151169
Moch, H., Humphrey, P. A., Ulbright, T. M. & Reuter, V. E. WHO Classification of Tumours of the Urinary System and Male Genital Organs. (France: International Agency for Research on Cancer, 2016).
Trpkov, K. et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod. Pathol. 34, 1392–1424 (2021).
pubmed: 33664427
doi: 10.1038/s41379-021-00779-w
Mali, S. A. et al. Making radiomics more reproducible across scanner and imaging protocol variations: A review of harmonization methods. J. Pers. Med. 11, 896 (2021).
doi: 10.3390/jpm11090842
Chatterjee, A. et al. Creating robust predictive radiomic models for data from independent institutions using normalization. IEEE Trans. Rad. Plasma Med. Sci. 3, 210–215 (2019).
doi: 10.1109/TRPMS.2019.2893860
Van Griethuysen, J. J. M. et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 77, e104–e107 (2017).
pubmed: 29092951
pmcid: 5672828
doi: 10.1158/0008-5472.CAN-17-0339
Ly, A. et al. High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. Nat. Prot. 11, 1428–1443 (2016).
doi: 10.1038/nprot.2016.081
Uppal, K., Ma, C., Go, Y. M. & Jones, D. P. XMWAS: A data-driven integration and differential network analysis tool. Bioinformatics 34, 701–702 (2018).
pubmed: 29069296
doi: 10.1093/bioinformatics/btx656
Doron, G., Klontzas, M. E., Mantalaris, A., Guldberg, R. E. & Temenoff, J. S. Multiomics characterization of mesenchymal stromal cells cultured in monolayer and as aggregates. Biotechnol. Bioeng. 117, 1761–1778 (2020).
pubmed: 32100872
doi: 10.1002/bit.27317
Pang, Z. et al. MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 49, W388–W396 (2021).
pubmed: 34019663
pmcid: 8265181
doi: 10.1093/nar/gkab382
Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE: Synthetic minority over-sampling technique. J. Artif. Intell. Res. 16, 321–357 (2002).
doi: 10.1613/jair.953
DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44, 837–845 (1988).
pubmed: 3203132
doi: 10.2307/2531595
Wilson, M. P. et al. Diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: A systematic review and meta-analysis. Abdom. Radiol. 45, 2532–2541 (2020).
doi: 10.1007/s00261-020-02469-8
Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964-983.e31 (2019).
pubmed: 31675502
pmcid: 7331093
doi: 10.1016/j.cell.2019.10.007
Pandey, N., Lanke, V. & Vinod, P. K. Network-based metabolic characterization of renal cell carcinoma. Sci. Rep. 10, 1–13 (2020).
doi: 10.1038/s41598-020-62853-8
Dizman, N., Philip, E. J. & Pal, S. K. Genomic profiling in renal cell carcinoma. Nat. Rev. Nephrol. 16, 435–451 (2020).
pubmed: 32561872
doi: 10.1038/s41581-020-0301-x
Kalarakis, G. et al. Combining contrast—enhanced ultrasound, CT perfusion and 99mTc-Sestamibi SPECT/CT to guide diagnosis in a case of solid renal tumour. BJR Case Rep. 7, 20200115 (2020).
pubmed: 33614118
pmcid: 7869121
Wang, W., Yang, C., Wang, T. & Deng, H. Complex roles of nicotinamide N-methyltransferase in cancer progression. Cell Death Dis. 13, 267 (2022).
pubmed: 35338115
pmcid: 8956669
doi: 10.1038/s41419-022-04713-z
Reustle, A. et al. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Clin. Transl. Med. 12, e883 (2022).
pubmed: 35678045
pmcid: 9178377
doi: 10.1002/ctm2.883
Lucarelli, G. et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget 6, 13371–13386 (2015).
pubmed: 25945836
pmcid: 4537021
doi: 10.18632/oncotarget.3823
Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104–116 (2016).
pubmed: 26766592
pmcid: 4809063
doi: 10.1016/j.ccell.2015.12.004
Mallat, S. & Zhong, S. Characterization of signals from multiscale edges. IEEE Trans. Pattern Anal. Mach. Intell. 14, 710–732 (1992).
doi: 10.1109/34.142909
Zhang, Z., Ma, S., Liu, H. & Gong, Y. An edge detection approach based on directional wavelet transform. Comput. Math. Appl. 57, 1265–1271 (2009).
doi: 10.1016/j.camwa.2008.11.013
Huerga, C. et al. Role of correlated noise in textural features extraction. Phys. Med. 91, 87–98 (2021).
pubmed: 34742098
doi: 10.1016/j.ejmp.2021.10.015
Klontzas, M. E. et al. Radiomics and machine learning can differentiate transient osteoporosis from avascular necrosis of the hip. Diagnostics 11, 1686 (2021).
pubmed: 34574027
pmcid: 8468167
doi: 10.3390/diagnostics11091686
Mühlbauer, J. et al. Radiomics in renal cell carcinoma—a systematic review and meta-analysis. Cancers (Basel) 13, 1348 (2021).
pubmed: 33802699
doi: 10.3390/cancers13061348
Kim, N. Y. et al. Utility of CT texture analysis in differentiating low-attenuation renal cell carcinoma from cysts: A bi-institutional retrospective study. AJR Am. J. Roentgenol. 213, 1259–1266 (2019).
pubmed: 31386573
doi: 10.2214/AJR.19.21182
Miskin, N., Qin, L., Silverman, S. G. & Shinagare, A. B. Differentiating Benign from malignant cystic renal masses: A feasibility study of computed tomography texture-based machine learning algorithms. J. Comput. Assist. Tomogr. 47, 376–381 (2023).
pubmed: 37184999
doi: 10.1097/RCT.0000000000001433